Columbia Laboratories Expands its Intellectual Property Portfolio Following Receipt of U.S. Patent

BOSTON, July 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it has expanded its intellectual property portfolio following the receipt of a patent covering bioadhesive progressive hydration tablets. The issued patent, U.S. Patent 8,765,177, pertains to a controlled, extended release delivery system for pharmaceutical compounds and can be used by the Company to develop proprietary products.

"The receipt of this patent is in keeping with our strategy of using the Company's patented delivery systems, combined with the formulation development capabilities of our wholly owned subsidiary, Molecular Profiles, to develop a portfolio of proprietary products. The patent could have a number of potential applications and increases our intellectual property portfolio pertaining to bioadhesive controlled release delivery of drugs," said Frank Condella, Columbia's president and chief executive officer.

In 2013, the Company was also granted a patent covering controlled-release pharmaceutical compositions using charged polymers, and the method of treating or preventing a disease using these new compositions. The patent, U.S. Patent 8,425,892, has a number of potential applications. It directly covers Columbia's extended release lidocaine vaginal gel (COL-1077), which had previously been developed through phase II for the treatment of pelvic pain and is currently under consideration for further development to prevent gynecological procedure related pain. There are currently no products approved for pain related to gynecological procedures.

About Columbia Laboratories

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry.  The Company has a successful heritage in developing pharmaceutical products, particularly in women's health.  Its most successful product to date, CRINONE® 8% (progesterone gel), is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  For more information, please visit www.columbialabs.com.

CRINONE^® is a registered trademark of Actavis, Inc. in the U.S.

Forward Looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," and similar expressions, which are generally not historical in nature. These include all statements relating to expected financial performance and future business or product developments.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.  For a discussion of certain risks and uncertainties associated with Columbia's forward-looking statements, please review Columbia's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2013.  

SOURCE Columbia Laboratories, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED